RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Olga Geling to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Olga Geling has written about Cost-Benefit Analysis.
Olga Geling
Connection Strength
0.059
Cost-Benefit Analysis
  1. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005 Feb 20; 23(6):1289-94.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support